PARADOX Trial: A Prospective, Double-Blind, Randomized Controlled Trial in Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli

Trial Profile

PARADOX Trial: A Prospective, Double-Blind, Randomized Controlled Trial in Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2016

At a glance

  • Drugs Apixaban (Primary)
  • Indications Embolism; Venous thrombosis
  • Focus Therapeutic Use
  • Acronyms PARADOX
  • Most Recent Events

    • 19 Jul 2016 Status changed from recruiting to withdrawn prior to enrolment.
    • 31 Dec 2015 Planned primary completion date changed from 1 May 2019 to 1 Jan 2020, according to ClinicalTrials.gov record.
    • 22 Sep 2015 Planned primary completion date changed from 1 Apr 2019 to 1 May 2019 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top